Evaluation of neuroinflammation biomarkers in brain cancer

Brain tumors comprise an extended variety of different neoplasms. Overall malignant CNS tumors represent 1.7% of newly diagnosed cancers and account for 2.1% of cancer deaths worldwide. Gliomasare the most common primary brain tumors of the central nervous system. Neuroinflammation is a common denominator in many neurological diseases. Neuroinflammation is a reaction to a disturbedenvironment that under physiological conditions can take place at very low levels, designed to restore balance in the central nervous system(CNS). There is a lot of information about the role of inflammation, inflammatory processes, and inflammation mediators in the pathogenesis of glioma.Noticeably, in glioma, the tumor microenvironment is an indispensable participant in the neoplastic process. Eventually, inflammatory molecules can cause reduction of cell-mediated cytotoxicity and potential immune evasion for tumors.NF-κB plays an important role in various biochemical interventions, including cell proliferation and apoptosis, and the development of immune and proinflammatory responses. Many human tumors have NF-κB abnormalities and not regulated, as NF-κB is permanently activated. Activating NF-κB activates the expression of genes that keep cell proliferation activity and keeps the cell against apoptosis. NF-κB that can create cellular conditions favorable for glioma promotion. On the other hand, this factor contributes to the supply of pro- inflammatory genes, including cytokines, chemokines, immune receptors, and other pro-inflammatory molecules. Activity Inappropriately, this factor triggers inflammatory mechanisms. Following the stimulation of the immune system, T cells Specific for tumor-associated antigen(TAA) expressed on brain tumor cells.NF-κB is one of Key mediators of cancer progression and inhibition it can be a way to prevent brain tumor progression.examinations of the effective immune response inside the CNS indicates that systemic immunity can safely enter the immunologically privileged CNS, selectively identify tumor-associated antigens, and destroy brain tumor cells. However, little is known about the migration patterns of tumor-specific T cells when targeting CNS tumors that can be the objectives of future researches